NicOx.... in attesa di..... (10 lettori)

tradermen

Forumer storico
Nicox CT : cible à 3.17 le 07/09/2010
2.23 est notre point pivot.

Notre préférence : cible à 3.17.

Scénario alternatif : l'enfoncement des 2.23, déclenchera un retour sur 1.91 puis 1.72.

Commentaire : le RSI est sous les 50. Le MACD est supérieur à sa ligne de signal et positif. Le dépassement de la zone des 50 sur le RSI validera une poursuite de la hausse. De plus, les cours sont au-dessus de leurs moyennes mobiles 20 et 50, situées actuellement sur 2.3865 et 2.4891.

Supports et résistances court terme :
3.36 *
3.17 **
2.97
2.51 (dernier)
2.36
2.23 **
1.91 *
 

Zohar

Forumer storico
Nicox CT : cible à 3.17 le 07/09/2010
2.23 est notre point pivot.

Notre préférence : cible à 3.17.

Scénario alternatif : l'enfoncement des 2.23, déclenchera un retour sur 1.91 puis 1.72.

Commentaire : le RSI est sous les 50. Le MACD est supérieur à sa ligne de signal et positif. Le dépassement de la zone des 50 sur le RSI validera une poursuite de la hausse. De plus, les cours sont au-dessus de leurs moyennes mobiles 20 et 50, situées actuellement sur 2.3865 et 2.4891.

Supports et résistances court terme :
3.36 *
3.17 **
2.97
2.51 (dernier)
2.36
2.23 **
1.91 *

Metto il grafico che forse ti eri dimenticato.
 

Allegati

  • coxeur100907154553.gif
    coxeur100907154553.gif
    14,8 KB · Visite: 678

simis

Encoxé à fond
Future Recommendations

Part of the uncertainty about NSAID use, including treat-
ment with COX-2 inhibitors, is due to the exclusion of
patients with CV disease from randomized controlled trials,
making it difficult to determine the true risks of NSAIDs for
CV disease. Another difficulty involves the choice of com-
parator ns-NSAIDs in trials of COX-2 inhibitors. Diclofe-
nac, for example, was used for comparison in clinical trials
assessing the efficacy of celecoxib and etoricoxib. However,
diclofenac has been associated with higher CV risk than
other ns-NSAIDs.
The dilution of relative risk associated with many
COX-2 inhibitors over successive studies combined with
the significantly lower rates of their prescription for recur-
rent heart failure suggests that prescribers have heeded
messages that NSAIDs may precipitate heart failure and
other heart conditions in vulnerable individuals and have
applied the same strategy in the use of COX-2 inhibitors.
Future research should include the development of new
medications for pain control. New classes of anti-inflam-
matory and analgesic agents are in development, such as
COX-inhibiting nitric oxide donators56 and selective E pro-
stanoid receptor antagonists.These agents may in-
duce less destabilization of BP control in treated patients
with hypertension, including patients taking renin-angioten-
sin system– blocking drugs.
Finally, of special importance
to cardiologists, the possibility of significant adverse inter-
actions between NSAIDs and angiographic contrast agents
should be studied.
 

gipa69

collegio dei patafisici
Io invece chiedo gentilmente il cancellamento dell'ultimo post:

Ve lo dico con estrema gentilezza.. la caccia alle streghe è compito dei mod. non il vostro, voi preoccupatevi di nicox e non degli utenti, perchè la democrazia prevede libertà di circolazione delle persone e delle idee e se voi non volete questo allora gli antidemocratici non sono i mod ma si annidano in questo thread.
Il bannamento degli utenti dal thread (e non dal forum) è stata una misura necessaria per far terminare le diatribe, se ricominceranno sarà mia cura bannare chiunque violi questa regola.

Per cui ora cancello il post sopra che nulla ha a che fare con il titolo.
 

Users who are viewing this thread

Alto